Table 3.
Variability in dalbavancin Cmin values in patients undergoing Cmin- or Cmax-based therapeutic monitoring (TDM).
| Cmin-Based TDM | |||
|---|---|---|---|
| Dalbavancin Cmin, mg/L (CV%) |
Days from the 1st Injection | Days from the Last Injection (range) |
|
| 2nd injection | 32 ± 14 (45%) | 10 ± 6 | 10 ± 6 (6–12) |
| 3rd injection | 14 ± 8 (57%) | 37 ± 14 | 33 ± 20 (14–50) |
| 4th injection | 15 ± 7 (43%) | 72 ± 30 | 29 ± 11 (20–35) |
| 5th injection | 17 ± 10 (56%) | 93 ± 27 | 32 ± 20 (14–57) |
| 6th injection | 15 ± 6 (41%) | 120 ± 30 | 28 ± 33 (21–42) |
| ≥6 injections | 19 ± 7 (37%) | 236 ± 63 | 31 ± 15 (14–43) |
| Cmax-based TDM | |||
| Dalbavancin Cmin, mg/L (CV%) |
Days from the 1st injection | Days from the last injection (range) |
|
| 2nd injection | 30 ± 13 (44%) | 8 ± 2 | 8 ± 2 (6–12) |
| 3rd injection | 16 ± 7 (46%) | 43 ± 6 | 36 ± 7 (20–47) |
| 4th injection | 11 ± 4 (40%) | 100 ± 46 * | 41± 3 ** (35–44) |
| 5th injection | 8 ± 2 * (21%) | 135 ± 18 ** | 45 ± 13 * (38–72) |
| 6th injection | 10 ± 3 (32%) | 178 ± 9 * | 45 ± 9 ** (39–63) |
| ≥6 injections | 11 ± 4 * (32%) | 297 ± 63 * | 43 ± 10 * (31–64) |
** p < 0.01 and * p < 0.05 versus Cmin-based TDM; CV%: Percent of coefficient of variation.